Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer

ConditionsUnresectable Colorectal Cancer Advanced Malignancy Elderly (People Aged 65 or More)

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age65+

SponsorJunpeng Wang

About this trial

We plan to conduct a prospective, two-arm, open-label phase Ⅱ study to evaluate whether transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab significantly improves the efficacy and safety compared with systemic FOLFOX therapy plus/minus cetuximab/bevacizumab in elderly patients with advanced unresectable colorectal cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 65 years, gender not restricted Pathologically confirmed advanced colorectal cancer without the opportunity for curative surgery Karnofsky Performance Status (KPS) score ≥ 60, with an estimated survival time ≥ 3 months At least 1 measurable colorectal lesion No prior systemic chemotherapy, or a minimum interval of 6 months between the last chemotherapy and study enrollment Voluntary signing of the informed consent form

Disqualifiers

Concomitant other malignant tumors Presence of gastrointestinal perforation Severe cardiovascular and cerebrovascular diseases Patients with hypersensitivity to study drugs or psychiatric disorders

Trial design

Design model

Parallel

Treatments tested in this trial

Transarterial chemoembolization
Procedure/Surgery
Transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumab

Treatment groups

50 Participants

are divided into 1 treatment group

Group A: transarterial chemoembolization with FOLFOX plus/minus intravenous cetuximab/bevacizumabExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Objective Response Rate；Disease Control Rate

Time frame

24 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Junpeng Wang

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Sponsor institution

Peking Union Medical College Hospital

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: